Cargando…
Expert committee to formulate policy and guidelines for approval of new drugs, clinical trials and banning of drugs-comments
All is not well with the clinical research industry. Instances of scientific misconduct by investigators, cutting corners by sponsors, irregularities by regulators, have brought a bad name to the industry. These however form a small part of the clinical research done in this country. The US FDA has...
Autor principal: | Ghooi, Ravindra B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4073545/ https://www.ncbi.nlm.nih.gov/pubmed/24987579 http://dx.doi.org/10.4103/2229-3485.134304 |
Ejemplares similares
-
Need for revision: EC process, members’ training, and compensation formula in the New Drugs and Clinical Trials Rules 2019
por: Ghooi, Ravindra Bhaskar
Publicado: (2022) -
Clinical trial agreements and insurance policies – role of the EC
por: Ghooi, Ravindra Bhaskar
Publicado: (2022) -
Ethics committee meetings – Online or face to face?
por: Ghooi, Ravindra Bhaskar
Publicado: (2020) -
Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022) -
South African experts comment on FDA approval of dabigatran inatrial fibrillation
por: E, Klug, et al.
Publicado: (2011)